PEG-MGF

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, polyethylene glycol-modified form of MGF, which is itself a splice variant of IGF-1 (Insulin-like Growth Factor 1) released in response to mechanical stress on muscle tissue. PEGylation dramatically extends the half-life from minutes to 24–72 hours, enabling less frequent dosing while preserving the satellite cell-activating and myoblast-proliferating properties of native MGF.

MGF is generated by alternative splicing of the IGF-1 gene in mechanically stressed muscle. Its unique C-terminal E-domain peptide activates quiescent muscle satellite cells — the resident stem cells responsible for muscle repair and hypertrophy. PEG-MGF binds IGF-1 receptors and MGF-specific receptors on muscle cell membranes, triggering downstream Akt/mTOR and MAPK/ERK signaling that promotes myoblast proliferation, differentiation, and fusion into new myofibers. The PEG modification (polyethylene glycol conjugation) shields the peptide from proteolytic degradation and renal clearance, extending systemic availability from the native MGF half-life of approximately 5–7 minutes to an estimated 24–72 hours.

Preclinical studies demonstrate PEG-MGF's ability to activate satellite cells and accelerate muscle repair following injury in rodent models, with significant gains in fiber cross-sectional area and reduced necrosis markers. It has shown promise for muscle-wasting conditions in animal models. No human clinical trials have been completed as of 2026. Community use among bodybuilders and recovery athletes is reported, but human pharmacokinetic data remain limited. It is often compared to IGF-1 LR3 but with a distinct tissue-remodeling profile.

Peptides commonly paired with PEG-MGF for synergistic effects.